➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Harvard Business School
McKesson
Merck
Medtronic

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,642,075


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,642,075
Title:Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Abstract: A system for treating or providing prophylaxis against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
Inventor(s): Weers; Jeff (Belmont, CA)
Assignee: Insmed Incorporated (Monmouth Junction, NJ)
Application Number:13/666,420
Patent Claims: 1. An aerosolized composition for the treatment of a pulmonary infection comprising free aminoglycoside in an amount effective to provide immediate bactericidal activity against the pulmonary infection and liposomal encapsulated aminoglycoside in an amount effective to provide sustained bactericidal activity against the pulmonary infection, wherein the lipid component of the liposome consists of electrically neutral lipids, and the aerosolized composition comprises droplets of an aqueous solution or suspension.

2. The aerosolized composition of claim 1, wherein the aminoglycoside is amikacin.

3. The aerosolized composition of claim 1, wherein the aminoglycoside is gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin or paromomycin.

4. The aerosolized composition of claim 1, wherein the liposomal encapsulated aminoglycoside comprises a mixture of unilamellar vesicles and multilamellar vesicles.

5. The aerosolized composition of claim 1, wherein the electrically neutral lipids comprise an electrically neutral phospholipid and a sterol.

6. The aerosolized composition of claim 1, wherein the electrically neutral lipids comprise a phosphatidylcholine and a sterol.

7. The aerosolized composition of claim 1, wherein the electrically neutral lipids comprise a phosphatidylcholine and cholesterol.

8. The aerosolized composition of claim 1, wherein the electrically neutral lipids comprise dipalmitoylphosphatidylcholine (DPPC) and a sterol.

9. The aerosolized composition of claim 1, wherein the electrically neutral lipids comprise dipalmitoylphosphatidylcholine (DPPC) and cholesterol.

10. The aerosolized composition of claim 1, wherein a ratio by weight of free aminoglycoside to the aminoglycoside encapsulated in the liposome is between about 1:100 and about 100:1.

11. The aerosolized composition of claim 1, wherein a ratio by weight of free aminoglycoside to the aminoglycoside encapsulated in the liposome is between about 1:10 and about 10:1.

12. The aerosolized composition of claim 1, wherein a ratio by weight of free aminoglycoside to the aminoglycoside encapsulated in the liposome is between about 1:2 and about 2:1.

13. The aerosolized composition of claim 2, wherein the liposomal encapsulated amikacin comprises unilamellar and multilamellar vesicles.

14. The aerosolized composition of claim 2, wherein the electrically neutral lipids comprise a phosphatidylcholine and a sterol.

15. The aerosolized composition of claim 2, wherein the electrically neutral lipids comprise a phosphatidylcholine and cholesterol.

16. The aerosolized composition of claim 2, wherein the electrically neutral lipids comprise a dipalmitoylphosphatidylcholine (DPPC) and a sterol.

17. The aerosolized composition of claim 2, wherein the electrically neutral lipids comprise a dipalmitoylphosphatidylcholine (DPPC) and cholesterol.

18. The aerosolized composition of claim 2, wherein a ratio by weight of free amikacin to the amikacin encapsulated in the liposome is between about 1:100 and about 100:1.

19. The aerosolized composition of claim 2, wherein a ratio by weight of free amikacin to the amikacin encapsulated in the liposome is between about 1:10 and about 10:1.

20. The aerosolized composition of claim 2, wherein a ratio by weight of free amikacin to the amikacin encapsulated in the liposome is between about 1:2 and about 2:1.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Express Scripts
Merck
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.